GlassScriptPhysician profile
Michelle Egler
NPI 1881990174
$3,863.73
in general payments reported to CMS, 2019-2025
37 companies · $965 in 2025
The $965 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $892 · 2023: $544 · 2024: $795 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $736.03 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $423.86 | 2021-2025 | |
| Lilly USA, LLC | $283.03 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.07 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $229.77 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $196.79 | 2021-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $191.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $171.08 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.85 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.31 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $112.91 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $94.10 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $81.50 | 2021 | |
| Merck Sharp & Dohme LLC | $78.94 | 2021-2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $77.13 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $67.69 | 2023-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $54.98 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.75 | 2024-2025 | Voquezna |
| Dexcom, INC. | $40.68 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $37.73 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.61 | 2021-2022 | |
| Lundbeck LLC | $36.60 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $34.13 | 2024-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $25.23 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.17 | 2025 | Caplyta |
| Biogen, INC. | $22.92 | 2025 | Zurzuvae |
| Acadia Pharmaceuticals INC | $20.52 | 2024 | Daybue |
| Teleflex LLC | $18.86 | 2024 | Urolift |
| Biocryst US Sales Co., LLC | $17.63 | 2025 | Orladeyo |
| Upsher-Smith Laboratories LLC | $17.11 | 2021 | |
| Myriad Women'S Health, INC. | $16.81 | 2023 | Myrisk |
| Currax Pharmaceuticals LLC | $15.45 | 2023 | Nexlizet, Contrave, Nexletol |
| Teva Pharmaceuticals USA, INC. | $15.40 | 2021 | |
| Corium, LLC | $14.91 | 2023 | Azstarys |
| Therapeuticsmd, INC. | $13.83 | 2021 | |
| Exeltis, USA INC. | $11.19 | 2021 | |
| Dynavax Technologies Corporation | $10.83 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Egler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.